False positive hepatitis C antibody test results in left ventricular assist device recipients

Increased risk with age and transfusions

Grace Y. Minamoto, Doreen Lee, Adriana Colovai, Dana Levy, Ljiljana Vasovic, Keith W. Roach, Jonathan Shuter, Daniel J. Goldstein, David D'Alessandro, Ulrich P. Jorde, Victoria A. Muggia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Left ventricular assist devices (LVADs) have been successfully used in patients with heart failure. However, LVADs may trigger immune activation, leading to higher frequencies of autoantibodies. We describe the clinical, epidemiological, and laboratory characteristics of LVAD recipients with false positive hepatitis C (FPHC) serology among 39 consecutive adult LVAD recipients who bridged to heart transplantation from January 2007 to January 2013 at Montefiore Medical Center. FPHC patients were identified as those with post-LVAD positive hepatitis C ELISA antibody tests and negative confirmatory testing with hepatitis C RNA PCR and/or radioimmunoblot assay. Ten (26%) patients previously seronegative for hepatitis C were found to have FPHC after device placement. Of the 39 patients, 32 had HeartMate II devices. The mean age at LVAD placement was 55 years. FPHC correlated with older age at the time of LVAD implantation and with receipt of packed red blood cell transfusions, but not with gender, fresh frozen plasma transfusions, panel reactive antibodies, globulin fraction, rheumatoid factor, or anticardiolipin antibodies. Clinicians should be aware of this increased risk of FPHC in older LVAD patients and those more heavily transfused in order to avoid unnecessary apprehension and possible delay in transplantation. Further studies should be done to evaluate the possible relationship between transfused blood products and immunomodulation.

Original languageEnglish (US)
Pages (from-to)205-210
Number of pages6
JournalJournal of Thoracic Disease
Volume9
Issue number1
DOIs
StatePublished - 2017

Fingerprint

Heart-Assist Devices
Hepatitis C Antibodies
Hepatitis C
Anticardiolipin Antibodies
Erythrocyte Transfusion
Equipment and Supplies
Immunomodulation
Rheumatoid Factor
Globulins
Serology
Heart Transplantation
Autoantibodies
Heart Failure
Transplantation
Enzyme-Linked Immunosorbent Assay
RNA
Polymerase Chain Reaction
Antibodies

Keywords

  • Allosensitization
  • Hepatitis c
  • Left ventricular assist device (LVAD)

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

False positive hepatitis C antibody test results in left ventricular assist device recipients : Increased risk with age and transfusions. / Minamoto, Grace Y.; Lee, Doreen; Colovai, Adriana; Levy, Dana; Vasovic, Ljiljana; Roach, Keith W.; Shuter, Jonathan; Goldstein, Daniel J.; D'Alessandro, David; Jorde, Ulrich P.; Muggia, Victoria A.

In: Journal of Thoracic Disease, Vol. 9, No. 1, 2017, p. 205-210.

Research output: Contribution to journalArticle

Minamoto, Grace Y. ; Lee, Doreen ; Colovai, Adriana ; Levy, Dana ; Vasovic, Ljiljana ; Roach, Keith W. ; Shuter, Jonathan ; Goldstein, Daniel J. ; D'Alessandro, David ; Jorde, Ulrich P. ; Muggia, Victoria A. / False positive hepatitis C antibody test results in left ventricular assist device recipients : Increased risk with age and transfusions. In: Journal of Thoracic Disease. 2017 ; Vol. 9, No. 1. pp. 205-210.
@article{3aec9cd487e844929da6dc95baa5f7aa,
title = "False positive hepatitis C antibody test results in left ventricular assist device recipients: Increased risk with age and transfusions",
abstract = "Left ventricular assist devices (LVADs) have been successfully used in patients with heart failure. However, LVADs may trigger immune activation, leading to higher frequencies of autoantibodies. We describe the clinical, epidemiological, and laboratory characteristics of LVAD recipients with false positive hepatitis C (FPHC) serology among 39 consecutive adult LVAD recipients who bridged to heart transplantation from January 2007 to January 2013 at Montefiore Medical Center. FPHC patients were identified as those with post-LVAD positive hepatitis C ELISA antibody tests and negative confirmatory testing with hepatitis C RNA PCR and/or radioimmunoblot assay. Ten (26{\%}) patients previously seronegative for hepatitis C were found to have FPHC after device placement. Of the 39 patients, 32 had HeartMate II devices. The mean age at LVAD placement was 55 years. FPHC correlated with older age at the time of LVAD implantation and with receipt of packed red blood cell transfusions, but not with gender, fresh frozen plasma transfusions, panel reactive antibodies, globulin fraction, rheumatoid factor, or anticardiolipin antibodies. Clinicians should be aware of this increased risk of FPHC in older LVAD patients and those more heavily transfused in order to avoid unnecessary apprehension and possible delay in transplantation. Further studies should be done to evaluate the possible relationship between transfused blood products and immunomodulation.",
keywords = "Allosensitization, Hepatitis c, Left ventricular assist device (LVAD)",
author = "Minamoto, {Grace Y.} and Doreen Lee and Adriana Colovai and Dana Levy and Ljiljana Vasovic and Roach, {Keith W.} and Jonathan Shuter and Goldstein, {Daniel J.} and David D'Alessandro and Jorde, {Ulrich P.} and Muggia, {Victoria A.}",
year = "2017",
doi = "10.21037/jtd.2017.01.10",
language = "English (US)",
volume = "9",
pages = "205--210",
journal = "Journal of Thoracic Disease",
issn = "2072-1439",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "1",

}

TY - JOUR

T1 - False positive hepatitis C antibody test results in left ventricular assist device recipients

T2 - Increased risk with age and transfusions

AU - Minamoto, Grace Y.

AU - Lee, Doreen

AU - Colovai, Adriana

AU - Levy, Dana

AU - Vasovic, Ljiljana

AU - Roach, Keith W.

AU - Shuter, Jonathan

AU - Goldstein, Daniel J.

AU - D'Alessandro, David

AU - Jorde, Ulrich P.

AU - Muggia, Victoria A.

PY - 2017

Y1 - 2017

N2 - Left ventricular assist devices (LVADs) have been successfully used in patients with heart failure. However, LVADs may trigger immune activation, leading to higher frequencies of autoantibodies. We describe the clinical, epidemiological, and laboratory characteristics of LVAD recipients with false positive hepatitis C (FPHC) serology among 39 consecutive adult LVAD recipients who bridged to heart transplantation from January 2007 to January 2013 at Montefiore Medical Center. FPHC patients were identified as those with post-LVAD positive hepatitis C ELISA antibody tests and negative confirmatory testing with hepatitis C RNA PCR and/or radioimmunoblot assay. Ten (26%) patients previously seronegative for hepatitis C were found to have FPHC after device placement. Of the 39 patients, 32 had HeartMate II devices. The mean age at LVAD placement was 55 years. FPHC correlated with older age at the time of LVAD implantation and with receipt of packed red blood cell transfusions, but not with gender, fresh frozen plasma transfusions, panel reactive antibodies, globulin fraction, rheumatoid factor, or anticardiolipin antibodies. Clinicians should be aware of this increased risk of FPHC in older LVAD patients and those more heavily transfused in order to avoid unnecessary apprehension and possible delay in transplantation. Further studies should be done to evaluate the possible relationship between transfused blood products and immunomodulation.

AB - Left ventricular assist devices (LVADs) have been successfully used in patients with heart failure. However, LVADs may trigger immune activation, leading to higher frequencies of autoantibodies. We describe the clinical, epidemiological, and laboratory characteristics of LVAD recipients with false positive hepatitis C (FPHC) serology among 39 consecutive adult LVAD recipients who bridged to heart transplantation from January 2007 to January 2013 at Montefiore Medical Center. FPHC patients were identified as those with post-LVAD positive hepatitis C ELISA antibody tests and negative confirmatory testing with hepatitis C RNA PCR and/or radioimmunoblot assay. Ten (26%) patients previously seronegative for hepatitis C were found to have FPHC after device placement. Of the 39 patients, 32 had HeartMate II devices. The mean age at LVAD placement was 55 years. FPHC correlated with older age at the time of LVAD implantation and with receipt of packed red blood cell transfusions, but not with gender, fresh frozen plasma transfusions, panel reactive antibodies, globulin fraction, rheumatoid factor, or anticardiolipin antibodies. Clinicians should be aware of this increased risk of FPHC in older LVAD patients and those more heavily transfused in order to avoid unnecessary apprehension and possible delay in transplantation. Further studies should be done to evaluate the possible relationship between transfused blood products and immunomodulation.

KW - Allosensitization

KW - Hepatitis c

KW - Left ventricular assist device (LVAD)

UR - http://www.scopus.com/inward/record.url?scp=85010468523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010468523&partnerID=8YFLogxK

U2 - 10.21037/jtd.2017.01.10

DO - 10.21037/jtd.2017.01.10

M3 - Article

VL - 9

SP - 205

EP - 210

JO - Journal of Thoracic Disease

JF - Journal of Thoracic Disease

SN - 2072-1439

IS - 1

ER -